Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 3Phase 1/2 1

Status

Completed 3Unknown 1Active not recruiting 1

Sponsor Class

OTHER 3NETWORK 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 5Endocrine 2NET 1

Conditions

Neuroblastoma 3Pheochromocytoma 2Paraganglioma 2Recurrence 1Neuroendocrine Tumors 1Neoplasms 1Ganglioneuroblastoma 1

Interventions

Cyclophosphamide 518Bevacizumab 488Carboplatin 424pembrolizumab 389Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 317Radiotherapy 296Nivolumab 247Doxorubicin 244Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171Prednisone 167fludarabine 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Has results × 3-Iodobenzylguanidine × Clear all
NCT00253435 2026-04-28

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 2 Completed
50 enrolled 12 charts
CNS

Neuroblastoma

NCT04385277 2025-10-27

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 2 Active not recruiting
41 enrolled 13 charts
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT02035137 2022-06-08

N2011-01

New Approaches to Neuroblastoma Therapy Consortium

Phase 2 Completed
114 enrolled 13 charts
CNS

Neuroblastoma

NCT00874614 2020-02-20

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 2 Unknown
74 enrolled 10 charts 1 FDA
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT01413503 2018-09-18

A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors

University of California, San Francisco

Phase 2 Completed
50 enrolled 7 charts
CNSEndocrine

Neoplasms, Paraganglioma, Pheochromocytoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡